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Abstract 
The aim of this work was to study the antifibrotic effect of pulmonary administration of tilorone to lung 25 
fibrosis. L-leucine coated tilorone particles were prepared and their aerosolization properties were 
analyzed using two dry powder inhalers (Easyhaler and Twister). In addition, the biological activity 
and cell monolayer permeation was tested. The antifibrotic effect of tilorone delivered by 
oropharyngeal aspiration was studied in vivo using a silica-induced model of pulmonary fibrosis in 
mice in a preventive setting. When delivered from the Easyhaler in an inhalation simulator, the 30 
emitted dose and fine particle fraction were independent from the pressure applied and showed dose 
repeatability. However, with Twister the aerosolization was pressure-dependent indicating poor 
compatibility between the device and the formulation. The formulation showed more consistent 
permeation through a differentiated Calu-3 cell monolayer compared to pristine tilorone. Tilorone 
decreased the histological fibrosis score in vivo in systemic and local administration, but only systemic 35 
administration decreased the mRNA expression of type I collagen. The difference was hypothesized to 
result from 40-fold higher drug concentration in tissue samples in the systemic administration group. 
These results show that tilorone can be formulated as inhalable dry powder and has potential as an oral 
and inhalable antifibrotic drug. 
  40 
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1. Introduction 
Idiopathic pulmonary fibrosis (IPF) is a severe progressive lung disease with poor prognosis. The 45 
median survival is 2 to 7 years from diagnosis and comparable to many malignant disorders (18, 37). 
There are two drugs in clinical use, pirfenidone and nintedanib, which can be used to slow down 
disease progression. Both drugs are new, expensive, and have a somewhat difficult adverse effect 
profile. In phase 3 clinical trials, over 90% of the patients reported at least one adverse effect (18, 37). 
Adverse effects of nintedanib are mainly GI-tract related e.g. nausea and diarrhea, while pirfenidone 50 
shows also skin related adverse effects e.g. phototoxicity and rash. Reports from recent real-life studies 
confirm the adverse effect profiles of these drugs on a population level (3, 6, 16).  
 
Tilorone is an old anti-viral drug which has been characterized as an interferon inducer (39). However, 
it also shows therapeutic effects that are independent of interferon induction (9, 39). Tilorone inhibits 55 
transforming growth factor ȕ (TGF-ȕ) signaling pathway (23), which has been shown to be upregulated 
in fibrotic lungs (2). Lung tissue of IPF patients also shown increased levels of the bone morphogenetic 
protein (BMP) inhibitor gremlin-1 (19). Rescue of BMP signaling, by administration of BMP-7, is 
antifibrotic in in vivo mouse models (24, 29). Tilorone has been shown to induce BMP signaling and 
act as an antifibrotic agent in vivo in a mouse model of pulmonary fibrosis (23). 60 
 
Local administration of drugs directly into the lungs is hypothesized to result in decreased 
adverse effects and cost. As the drug is only administered to the affected organ, it would likely 
lead to lower total doses and result in decreased systemic exposure. For example, the dose of 
inhaled corticosteroids in modern asthma treatment is only a fraction of the dose used in oral 65 
administration (1). This has enabled the long term use of a drug class that otherwise would have 
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elicited severe adverse effects by systemic dosing. Pulmonary administration has been studied and 
proposed also for the currently used IPF drug pirfenidone (12, 30, 38, 43) and N-acetylcysteine (7, 31). 
 
Previously we have developed a method, the aerosol flow reactor method, which has been successfully 70 
employed for particle production of both freely and poorly water-soluble drugs and their combinations 
as carrier free inhalable dry powders (34, 40, 41). It is a one-step continuous process to simultaneously 
produce, encapsulate, and coat drug particles resulting in highly flowable and dispersible dry powders. 
Particles are encapsulated and coated with the amino acid L-leucine producing two qualitatively 
different L-leucine layers. The encapsulation formed via leucine diffusion to the particle¶V surface (10, 75 
27) protects the drug from moisture (36). The coating, which is formed via the physical vapor 
deposition of leucine, is composed of nano-sized crystals of leucine to form a rough coating. These 
nanocrystals allow firstly, the spatial separation of the particles and secondly, a reduction of the contact 
area to lower adhesion forces between particles and surfaces (32). These properties are imperative for 
good dispersion properties of dry powders (34). 80 
 
The aim of this work was to promote the therapeutic potential of tilorone, a known antifibrotic small 
molecule, via the lungs using dry powder inhalation (DPI) delivery. For this, we prepared L-leucine 
coated tilorone dry particles, which were analyzed for their aerosolization properties, cell permeation 
and in vitro activity. Finally, the antifibrotic effect of tilorone in pulmonary administration was studied 85 
in a mouse model of silica-induced fibrosis. 
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2. Materials and methods 
 90 
2.1. Preparation of the aerosol nanoparticles 
Tilorone (5 g/L, Hangzhou Pharma & Chem), D-mannitol (10 g/L, Alfa Aesar) and L-leucine (10 g/L, 
Alfa Aesar) were dissolved in deionized water to produce a precursor solution for the aerosol 
processing. The aerosol flow reactor method has been discussed in detail in previous studies  (8, 26, 
33). Briefly, the solute droplets were generated by an ultrasonic nebulizer (RBI Pyrosol 7901) and 95 
transferred with nitrogen gas (20 L/min) to the stainless steel aerosol reactor (diameter 100 mm and 
length 1800 mm) where temperature was set to 180 °C (± 1 °C). As a surface active agent, L-leucine 
accumulated in the air-liquid interface from where it was sublimated by the reactor¶V 
temperature.(10, 27) This process generated a cloud of L-leucine around the particles. At the 
reactor downstream, the aerosol was rapidly diluted and cooled with a large volume of pressurized air 100 
(22 °C, 80 L/min; Reynolds number > 3000) in a porous stainless steel tube to avoid the wall 
deposition of particles and to initiate nucleation and deposition of leucine vapor on drug particle 
surfaces. The aerosol flow were then lead to a small-scale cyclone (height 85 mm, body diameter 
35 mm, exit tube length 45 mm, and exit and inlet tube diameter 10 mm) where the solid aerosol 
particles were collected (45). 105 
 
2.2. Particle morphology 
The particle morphology was studied with field-emission scanning electron microscope (Zeiss 
Sigma VP) with acceleration voltage of 2 kV. The samples were coated with sputtered platinum 
to enhance image contrast and to stabilize the particles under the electron beam. 110 
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2.3. Analysis of powder composition 
The composition of the powder was determined using proton nuclear magnetic resonance spectrometry 
(1H-NMR) (Bruker AVANCE 400 MHz) in D2O. Chemical shifts used were for tilorone: Ɂ = 1.2 ppm 115 
(6H), L-Leucine: Ɂ = 1.6 ppm (3H) and D-Mannitol Ɂ = 4.5 ppm (2H). 
 
2.4. Powder aerosolization 
All the fine powders were stored in a desiccator over silica gel (0±1% of relative humidity) prior to the 
inhalation experiments. The aerosolization of the carrier-free powders was studied using a computer-120 
assisted inhalation device developed in-house. Its detailed operating principles have been discussed 
elsewhere (17, 20) and its applicability for the aerosolization of powders has been demonstrated (20, 
34). Briefly, the inhalation profile is created through interplay between a vacuum and pressurized air 
gas by a controlled valve system (see supplementary Fig. 1). The low pressure impactors require 
stable flow to accurately sort the particles according to their aerodynamic diameter. In between 125 
the actuations, the device is fed by a bypassed flow to ensure constant mass flow to the analysis 
instrumentation while giving zero net flow to the mouth piece of the inhaler. The bypassed flow is 
led to the instrument through a porous metal tube to create a particle-free film on the edge of the 
flow. When the actuation is initiated, the controlled valve system diverts part of the bypassed 
flow to the inhaler mouth piece resulting in emission of the powder. The laminar particle free 130 
flow on the surface of the tubing prevents particle collision with the tubing and therefore ensures 
that the particle agglomerates are not broken by the instrument after they leave the inhaler. 
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Two inhalers, multi-dose reservoir-type Easyhaler inhaler (Orion Pharma) and single-dose capsule 
Twister inhaler (Aptar Pharma), were used. The Easyhaler reservoir was filled with approx. 0.8 g of 135 
fine drug powder, and the hydroxypropyl methylcellulose (HPMC) capsules (Vcaps size 3, Capsugel) 
used in Twister were filled with 5.0 ± 0.1 mg/capsule of fine drug powder. Doses to the inhalers were 
conveyed as instructed by the providers. Prior to the actual inhalation experiments, five powder doses 
were run and discarded. Powder emission (emitted dose, ED, 10 repetitions) was detected 
gravimetrically by weighing the inhaler or inhaler and capsule before and after each inhalation. 140 
Pressure drops over the inhalers were adjusted to 2 and 4 kPa corresponding to the inspiration flow 
rates of 40 L/min
 
and 55 L/min for Easyhaler and 43 L/min and 55 L/min for Twister. The inhalation 
profiles were fast, i.e., the maximum pressure drops and flow rates were achieved in two seconds 
maintaining these sets for 8 s and then stopped. Fine particle fractions (FPF, the fraction of particles 
with the geometric number mean diameter (Dg) size less than 5.5 µm) were measured gravimetrically 145 
on collection stages of a Berner-type low pressure impactor (BLPI) (15). The dispersed fine particles 
were collected isokinetically by the BLPI (15) with a stage aerodynamic cut-off diameters ranging from 
0.03 to 15.61 µm. Mass median aerodynamic diameters (MMAD) and related geometric standard 
deviations (GSD) of the deposited powders were determined by  
 150 ܯܯܣܦ ൌ ቆ  ?ሺ݉௜  ܦ௜ሻܯ ቇ 
 
ܩܵܦ ൌ ൮ቌ ? ቀ݉௜ܦ௜ଷሺܦ௜ െ ܯܯܣܦሻቁଶ ?ሺ݉௜ܦ௜ଷሻ െ  ? ቍଵȀଶ൲ 
 
8 
 
  
respectively, where mi is the mass fraction of particles on the collection stage, Di is the mean 
aerodynamical diameter of the particles at the collection stage, and M is the sum of mass fractions and 155 
is, by definition, unity. Fine particle fractions (FPF, Dg ื 5.5 µm) were expressed with reference to the 
emitted dose (ED). 
 
2.5. Cell culture 
Calu-3 (HTB-55) human airway epithelial cells were obtained from American Type Culture Collection 160 
(ATCC). Cells from passages 35±38 were used in the experiments. TGF-ȕ [(CAGA)12-luc] and BMP 
[(Bre)2-luc] pathway reporter cell lines (A549 lung adenocarcinoma cells, CCL-185, ATCC) were 
produced as described elsewhere (23). The cHOOV ZHUH FXOWXUHG LQ 'XOEHFFR¶V 0RGLILHG (DJOH¶V
Medium (DMEM, HyClone) supplemented with 10% FBS, 1% L-glutamine, 100 IU/ml penicillin, 100 
ȝg/ml streptomycin (all from HyClone). Reporter cell lines were cultured in the presence of 0.4 mg/ml 165 
G418 (Sigma-Aldrich). The cultures were maintained in a MCO 170-M multi-gas incubator at 37°C 
(Panasonic Biomedical) in an atmosphere of 5% CO2 and 95% relative humidity. The growth medium 
was changed three times per week. 
 
2.6. In vitro drug permeation  170 
The permeability of tilorone powder (formulated or unprocessed) across a differentiated Calu-3 lung 
cell monolayer was measured as described  elsewhere (40). Briefly, cells were seeded into Transwell 
inserts (ȝPSRUHs size, surface area of 1.12 cm2, Costar) at a density of 5×105 cells/cm2. To promote 
the differentiation of the Calu-3 cells, an air-liquid interface was induced by removing the media from 
the apical side 24 h after seeding. The cells were then allowed to differentiate for 14±22 days. The 175 
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integrity of the Calu-3 cell monolayer and tight junction barrier function were assessed before and after 
the permeation experiment by measuring the transepithelial electrical resistance (TEER) using a 
Millicell Electrical Resistance System (Millipore). Before the deposition experiment, the medium from 
the basolateral compartment was replaced with fresh PBS. Afterwards, 10 µL of Curosurf lung 
surfactant (Chiesi Farmaceutici) which contains polar lipids, in particular 180 
dipalmitoylphosphatidylcholine (DPPC, ׽50% of the total phospholipid content), was gently pipetted 
on top of the cell monolayer in the apical compartment. Subsequently, approximately 2 mg of the 
formulated tilorone or 1 mg of unprocessed tilorone was deposited in each of the wells. The samples 
were collected over a period of 180 min by sampling 500 µL from the basolateral compartment and 
replacing the taken volume with fresh PBS. 185 
 
The tilorone concentration in the samples was determined using a Hewlett Packard series 1100 liquid 
chromatography system (Hewlett Packard) with ultraviolHW GHWHFWLRQ Ȝ    QP. The 
chromatographic separation was performed on a Kinetex EVO C18 column (2.6 Pm particle size, inner 
diameter 4.6 mm × 150 mm, Phenomenex).  190 
 
The mobile phase consisted of 100 mM formic acid in water (A), and acetonitrile (B) in an 82:18% v/v 
ratio (isocratic run, total run time 6 min). The mobile phase flow rate was set at 700 PL/min and the 
injection volume was 10 µL.  The amount of permeated tilorone was calculated in relation to the 
original drug amount present in the dry powder particles. The results are the averages of four 195 
independent experiments  
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2.7. TGF-ȕ%03Ouciferase reporter assays 
TGF-ȕ [(CAGA)12-luc] or BMP [(Bre)2-luc] pathway reporter cells were seeded into 96-well plates 
(1.5-2×10
4
/well) and allowed to attach for 5 hours. Stimulation media containing 5% FBS and different 200 
concentrations of tilorone powders were added to the cells. TGF-ȕ (0.5 ng/ml) or BMP-4 (5 ng/ml) was 
used as a positive control. Cells were stimulated for 18h after which they were lysed and subjected to 
luciferase activity measurements using the Luciferase Assay System (Promega) measured with DCR-1 
luminometer (MGM Instruments) as previously described (23). Three independent assays were 
performed. 205 
 
2.8. In vivo mouse model of pulmonary fibrosis 
Experiments involving mice were approved by the Finnish national animal experiment board 
(ESAVI/10418/04.10.07/2016) and carried out in accordance with institutional guidelines, which fulfill 
the requirements defined in regulations of the Finnish Act on the Protection of Animals used for 210 
Scientific or Educational Purposes (497/2013) and were performed according to the 3R.  
 
To induce pulmonary fibrosis, a modified version of the method described by Lakatos et al. was used 
(22). Male C57b6/J mice (Envigo) were exposed to silicon dioxide (SiO2, 50 mg/kg in 50 µL PBS, 
Sigma-Aldrich) by two subsequent oropharyngeal aspiration doses on days 1 and 5 as previously 215 
described (23). The mice were treated with tilorone three times a week for three weeks starting on day 
1. For systemic administration, the mice were given tilorone (50 mg/kg) by intraperitoneal injection. 
For pulmonary administration, the tilorone formulation was dissolved in sterile PBS and administered 
by oropharyngeal aspiration (tilorone dose 5 mg/kg). The vehicle group (pulmonary administration) 
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received excipients (L-leucine and D-mannitol) dissolved in sterile PBS at same doses as the group 220 
receiving the tilorone formulation.  
 
All mice were sacrificed on experiment day 22. The entire left lung was fixed in 4% paraformaldehyde 
and embedded in paraffin. The right lung was snap frozen in liquid nitrogen and stored at -70 °C. To 
produce homogenous lung tissue powder for subsequent analyses, the right lung was crushed with 225 
mortar and pestle under liquid nitrogen.  
 
2.9. Histological analyses 
Lung tissue sections (3 µm) were stained with hematoxylin and eosin for histological evaluation. The 
degree of pulmonary fibrosis and inflammation was evaluated using a semi-quantitative scale from 0-3 230 
allowing half steps. The scoring was performed by two blinded researchers and in case of disagreement 
the scoring was discussed until consensus was found. For the histological micrographs the slides were 
scanned digitally (Pannoramic FLASH II, 3DHistech) and analyzed using CaseViewer program 
(3DHistech). 
 235 
2.10. RNA isolation and quantitative RT-PCR 
Total lung tissue RNA was isolated with RNeasy Mini Kit (Qiagen) and RNA integrity was analyzed 
using TapeStation (Agilent Technologies) at the Biomedicum Functional Genomics Unit (HiLife, 
Helsinki). Complementary DNA was synthesized with iScript cDNA Synthesis Kit (BioRad).  The 
cDNAs were amplified using TaqMan Assays-on-Demand gene expression products (Applied 240 
Biosystems) and CFX96 Real-time PCR detection system (Bio-Rad). The relative gene expression 
differenceVZHUHFDOFXODWHGZLWKWKHFRPSDUDWLYHǻǻ&7PHWKRGDQGWKHUHVXOWVKDYHEHHQH[SUHVVHGDV
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mRNA expression levels normalized to the levels of a gene with a constant expression (TBP, TATA-
binding protein). 
 245 
2.11. Analyses of drug tissue concentrations 
The lung samples were processed according to the procedure by Zhang et al (44).The homogenized 
tissue samples were weighed and purified water was added to reach a final volume of 200 µl. 
Calibration samples were prepared in human plasma. Metoprolol (Toronto Research Chemicals) was 
used as an internal standard. The drug concentrations were determined by using a Shimadzu Nexera 250 
liquid chromatography system (Shimadzu Corporation) coupled to a Shimadzu Nexera 8050 tandem 
mass spectrometer (Shimadzu Corporation). The chromatographic separation was performed on Waters 
XBridge C18 column (3.5 µm particle size, inner diameter 2.1 mm x 100 mm, Waters Corporation) 
equipped with Waters XBridge C18 pre-column. The mobile phase consisted of 10 mM ammonium 
acetate in water (pH 9.5) (A) and methanol (B) (gradient separation, 5-100% B, total run time 7 min). 255 
The mobile phase flow was set at 300 µl/min and the injection volume was 10 µl. The mass 
spectrometry detection was performed using electro-spray ionization in positive mode and monitoring 
multiple reactions of the [M+NH4]+  (tilorone) or [M+H]+  (metoprolol)  precursor ions to the product 
ions for analyte and internal standard as follows: m/z 427 ±>86 for tilorone, and 268 ±> 116 m/z for 
metoprolol. The lower limit of quantification (LLOQ) was 1 ng/ml and day-to-day repeatability 12.8%. 260 
 
2.12. Statistical analysis 
The numerical data are presented as the mean ± standard deviation (SD). Data from activity and in vivo 
-experiments were analyzed for statistical significance with nonparametric Mann-Whitney test using 
SPSS Statistics 24 software (IBM). For the permeation experiment, a multiple t-test followed by a 265 
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Holm-âtGiN correction test (significance level, alpha, set to 5%) was used to compare all individual 
data points. P-values less than 0.05 were considered significant. 
 
3. Results 
3.1. Particle morphology and composition  270 
 We first attempted to produce tilorone dry powder with leucine as the only excipient. This was not 
successful as the particles strongly agglomerated and aggregated showing cuboid rather than spherical 
morphology upon collection by cyclone (Supplementary Fig. 2). It is likely that tilorone did not 
crystallize upon particle formation but remained in an amorphous state in the particles. However, once 
collected tilorone started to crystallize resulting in sintered, aggregated particles. Sintering prevents the 275 
dispersion of the produced single particles upon inhaler actuation, resulting in aerosolized aggregates 
that are too large for deep lung deposition. The excipient mannitol was added as a reinforcing matrix 
component to reduce or even prevent the sintering by dilution. It has been shown that mannitol 
crystallizes in the aerosol particle production (21) . Being more stable than amorphous, the crystalline 
state is more resistant to phase changes in both collection and storage. Addition of mannitol resulted in 280 
stable particle morphology and particle agglomeration was avoided.  
 
The powder formulation contained 29.4 m-% of tilorone, 9.6 m-% of leucine and 61.0 m% of mannitol 
as determined by proton-NMR (NMR spectrum in supplementary Fig. 3). The SEM micrograph of 
tilorone dry powder (Fig. 1) shows spherical particles with the rough leucine coating. Some 285 
aggregation is observed with the larger particles, which could be real agglomeration or an artefact 
formed during sample preparation for the SEM.  
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3.2. Powder aerosolization 
To allow reliable dosing despite age, gender, or clinical state of the patient, the dry powder formulation 290 
needs to aerosolize and disperse in a pressure and flow rate-independent manner. Tilorone dry powder 
showed good aerosolization characteristics especially when delivered from the Easyhaler inhaler (Table 
1). In case of applying Easyhaler, the ED and FPF showed virtually no pressure dependence. Dose 
repeatability in the ED described by CVED was well within acceptable limits, being under 10 % for both 
pressure drops. However, when delivered from the Twister inhaler the aerosolization performance of 295 
the tilorone powder was more dependent on the applied pressure drop. At 2 kPa, the ED was 17 % 
higher and the FPF was 33 % lower than the corresponding results carried out at 4 kPa. These 
differences could lead to clinically significant variation in dosing depending on the clinical state of the 
patient. Dose repeatabilities (CVED) for the ED were acceptable, but showed some variation as function 
of pressure drop.  300 
 
3.3. Biological activity of the formulation in vitro 
The aerosol flow reactor method involves heating of the drug up to 180 
°
C during droplet drying and 
leucine sublimation process. Since many chemical compounds are unstable at such temperatures, we 
studied the biological activity of the tilorone formulation in an in vitro setting. The activity was 305 
analyzed using two luciferase reporter assays (see Methods). We have previously shown that tilorone 
decreases TGF-ȕ and increases BMP signaling activity in lung epithelial cells (23) . The formulation 
showed a concentration dependent response in both inhibition of TGF-ȕ VLJQDOLQJ and induction of 
BMP signaling suggesting retained biological activity (Fig. 2). Also, there was no statistically 
significant difference in the activity of the formulation when compared to its pristine counterpart at 310 
equal tilorone doses.  
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3.4. Cell monolayer powder permeation in vitro 
Effective DPI formulations require the powder to adhere onto the lung walls in order to allow drug 
molecules to permeate the pulmonary epithelium or at least become freely available for absorption in 315 
the lung parenchyma in order to achieve a therapeutic effect (13, 14). The permeability of formulated 
and unprocessed tilorone powders was measured across a differentiated Calu-3 lung cell monolayer in 
the apical to basolateral direction. The TEER was measured before and after the experiments to assert 
monolayer integrity. The average value obtained for all the wells before the deposition was 514 ± 39 
ȍcm2, which is in good agreement with values reported in the literature (14) . However, a sharp decline 320 
in TEER values (over 37%) was registered after the experiment, which is likely to be related to the 
introduction of the Curosurf surfactant in the apical compartment. Curosurf contains roughly 50% 
DPPC, a phospholipid known to substantially decrease TEER values of Calu-3 differentiated cell 
monolayers therefore allowing increased drug permeation (4) . In the case of unprocessed tilorone 17.6 
% of the deposited drug was able to permeate through Calu-3 cell monolayer, whereas only 11.2 % of 325 
the formulated tilorone permeated (Fig. 3). The differences were found not to be statistically 
significant. However, the formulated powder showed less variation and therefore, more consistent 
permeation.  
 
3.5. Pulmonary administration of tilorone in vivo  330 
The antifibrotic activity of tilorone delivered using pulmonary administration was studied using a 
silica-induced pulmonary fibrosis model in mice.  The mice were divided into four groups (n=12) upon 
arrival; the first group was assigned as control and did not receive fibrosis induction or any treatment 
(non-treated), the second group was exposed to silica and received only excipients (mannitol and 
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leucine) through aspiration (SiO2-ctrl), the third group was exposed to silica and received tilorone 335 
through intraperitoneal injection (SiO2-systemic) and the fourth group was exposed to silica and 
received dissolved tilorone microparticles through aspiration (SiO2-local). Mice exposed to silica 
suffered a weight loss of 1-2 g after both silica exposures (Supplementary Fig 4).  Otherwise there were 
no observable adverse effects due to silica exposure or pulmonary administration. There was no 
observed mortality during the experiment in any of the groups. 340 
 
Histological analyses of lung tissue indicated that both systemically and locally administered tilorone 
decreased fibrotic alterations (Fig 4A). In agreement with our previous reports (23), histological 
scoring indicated that systemic administration of tilorone significantly decreased fibrosis (p=0.013) and 
inflammation (p=0.010) in fibrotic mice (Fig. 4B). Local dosing also resulted in a significantly lower 345 
fibrosis score (p=0.028). However, the inflammation score showed only a non-significant decrease in 
the locally treated group (p=0.103).  
 
To analyze the effect of locally administered tilorone on pulmonary parenchyma matrix deposition, the 
mRNA expression of type I collagen (Col1a1) was measured from homogenized lung tissue samples. 350 
Col1a1 expression increased in response to SiO2-exposure and was reversed by systemic tilorone 
administration (Fig. 5, p=0.010). Local dosing had no effect on Col1a1 expression. 
 
To assess the pharmacokinetic properties of tilorone in pulmonary administration, tilorone 
concentrations were measured from the homogenized lung tissue samples. The non-treated and control 355 
groups did not receive tilorone and no tilorone could be detected in these groups, as expected. For the 
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systemic administration group the tilorone content was 507.4±50.5 µg/ml and for the local 
administration group, it was 12.1±1.2 µg/ml. 
 
 360 
4. Discussion 
Effective drug delivery to the lung parenchyma can be achieved by a well-performing inhalation 
product that is correctly administered to the patient. One of the inhalation platforms is dry powder, 
where micronized drug particles with size < 5 µm, suitable for delivery to alveolar region, (42) are 
delivered from DPI inhalers. These particles, however, are usually very cohesive (28) resulting in poor 365 
flowability and dispersibility. This is why the particles are usually blended with coarser carrier particles 
to ensure dose repeatability upon inhalation. Particle engineering plays an important role in the 
fabrication of carrier-free formulations with accurate dosing and delivery properties. Our carrier-free 
tilorone formulation showed pressure independent behavior especially with Easyhaler. The tilorone 
formulation shows somewhat lower FPF than our previous leucine-based formulations with 370 
corticosteroids or corticosteroid-ȕ-agonist combination.(35, 40, 41) However, ED and CV are well 
in line with our previous formulations. It is possible, that the presented tilorone formulation is 
suboptimal and could further be improved by addition of excipients or careful adjustment of the 
L-leucine saturation conditions.  
 375 
As tilorone is a freely water-soluble compound, drug solubility is not a significant bottleneck for its in 
vivo administration and biodistribution. However, as the unprocessed tilorone powder has unequal 
particle size it is likely to produce uneven permeation profiles leading to potential dose-dumping 
effects. By formulating tilorone as a DPI, which enables precise control over drug content, particle size, 
18 
 
and morphology, it is possible to achieve more reproducible drug release profiles. The presented results 380 
highlight the value of processing even freely water-soluble compounds as DPIs, where precise control 
over are particle size and drug dosing play a critical role for clinical translation.   
 
While the mechanism of action of the oral antifibrotic agent pirfenidone is not completely understood, 
it has been shown to prevent TGF-ȕ LQGXFHGSUROLIHUDWLRQ and fibrogenic activity of primary human 385 
OXQJILEUREODVWVDQGKXPDQ7HQRQ¶VILEUREODVWVin vitro (5, 25). Therefore, it seems to share at least one 
common pathway with tilorone. Pulmonary formulations of pirfenidone have been studied in both in 
vitro and in vivo. Seto et al. (38) studied the pharmacokinetic profile of spray dried pirfenidone and 
showed that at pharmacologically effective doses pulmonary delivery resulted in a 600-fold lower 
systemic exposure than oral doses in rat. In continuation of the work, Onoue et al. (30) showed that 390 
drug exposure in skin and eyes was 90-130-fold less in pulmonary than in oral administration. Along 
with the success of inhaled corticosteroids in asthma treatment this suggests that the harm-benefit-
profile of antifibrotics can be improved through pulmonary administration, which could be beneficial 
also when considering combination therapy in the treatment of IPF. 
 395 
In this study, we show that an efficient antifibrotic effect can be achieved using a TGF-ȕ/BMP 
modulating small molecule, tilorone, by using local administration in a well-established mouse model 
of pulmonary fibrosis.  However, systemic dosing resulted in less fibrosis in histological analysis, as 
well as significantly lower collagen expression and anti-inflammatory effect, which was not seen in 
local administration. Better treatment results of systemic dosing can be explained by the measured drug 400 
concentration at the site of action as the measured lung tissue concentration in the pulmonary 
administration group was only approximately 2.5% of the concentration of the systemic group. As the 
local dose was 10% of the systemic dose, the difference in concentration is higher than would be 
19 
 
expected from the difference in doses alone suggesting that either the delivery by aspiration is 
incomplete or the drug was cleared before penetrating the pulmonary epithelium. It is likely that even 405 
though the swallowing of the mice was prevented by holding the tongue during drug administration, a 
portion of the dose remained outside the airways e.g. in pharynx and was swallowed afterwards. 
Unfortunately, we were unable to determine blood concentration of tilorone due to technical 
difficulties, but Golovenko and Borisyuk (11) reported that there was no apparent accumulation of 
tilorone in lung tissue when compared to blood concentration in peroral administration. To the authors¶ 410 
knowledge, there have been no studies on the pharmacokinetics of tilorone in pulmonary 
administration. Determination of the optimal dosing and further development of the formulation, e.g. 
by adding permeation enhancers, could yield significant improvements in treatment results. 
 
In conclusion, the data presented here shows that tilorone can be formulated to a reliable and 415 
well performing inhalable dry powder. We have shown that the powder retains its biological 
activity despite the high reactor temperature, and that our formulation promotes more consistent 
permeation through a lung cell monolayer. Furthermore, the results from in vivo studies show 
that tilorone is a promising antifibrotic agent in both systemic and pulmonary administration.  
 420 
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 555 
Figure Captions 
 
 
Figure 1. Scanning electron micrograph of leucine coated tilorone particles. Leucine forms rough 
crystalline surface on the drug particles.  560 
 
Figure 2. Effect of tilorone on TGF-ȕ$DQG%03%VLJQDOLQJSDWKZD\V7LORURQHwas shown to 
inhibit TGF-ȕDQGLQGXFH%03 pathway in a concentration dependent manner. No statistically 
significant difference was seen between unprocessed and formulated drug. The results are expressed on 
a relative scale where the negative control was set to have the value 1. Reported values are averages of 565 
three independent experiments and the error bars represent the standard error of mean (SE). The data 
were analyzed for statistical significance with nonparametric Mann-Whitney test. Asterisk indicates 
statistically significant (p < 0.05) difference compared to negative control. 
 
Figure 3. Drug permeation across a differentiated Calu-3 cell monolayer. There was no statistically 570 
significant difference between formulated and unprocessed tilorone powder in drug permeation 
profiles. Results are averages of four independent experiments and the error bars represent the standard 
error of mean (SE). To compare individual data points a multiple t-test followed by a Holm-âtGiN 
correction test (significance level, alpha, set to 5%) was used. 
 575 
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Figure 4 Histological analysis of mouse lung tissue.  Representative images of hematoxylin and eosin 
stained tissue from non-treated control group (A, non-treated), silica-exposed control group (B, SiO2-
Ctrl), systemic treatment group (C, SiO2-Systemic) and local treatment group (D, SiO2-Local) are 
shown. Systemic administration of tilorone resulted in a decrease of histological scoring for both 
fibrosis and inflammation when compared to SiO2-Ctrl group. Local dosing resulted in a decrease in 580 
the histological scoring of fibrosis. Mean value is reported for each group (n=12). The error bars 
represent the standard error of mean (SE). The data were analyzed for statistical significance with 
nonparametric Mann-Whitney test. Asterisk indicates statistically significant (p < 0.05) difference 
compared to SiO2-Ctrl group. 
 585 
Figure 5. Type I collagen (Col1a1) mRNA expression. Silica exposure increased the expression in 
exposed controls (SiO2-Ctrl). Systemic administration resulted in a significant decrease of type I 
collagen expression. Mean value is reported for each group (n=12) and the error bars represent the 
standard error of mean (SE). The data were analyzed for statistical significance with nonparametric 
Mann-Whitney test. Asterisk indicates statistically significant (p < 0.05) difference compared to SiO2-590 
Ctrl group. 
 
Tables  
Table 1: Aerosolization results of the carrier-free fine powders formulation  
 595 
 
 
 
 
ED (mg) CV (%) FPF (%) MMAD (µm) GSD (µm) ED_eff (%) 
2 kPa EH 3.0 9 28 3.3 1.7 
 4 kPa EH 3.0 8 30 3.8 1.7  
2 kPa Tw 4.8 7 22 3.4 1.7 95 
4 kPa Tw 4.1 11 33 3.2 1.7 81 
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Actuation from Easyhaler (EH) and Twister (Tw) at two pressure drops and inhalation flow rates. For 
Easyhaler 2 kPa = 43 L/min and 4 kPa = 55L/min, and for Twister 2 kPa = 40 L/min and 4 kPa = 55 600 
L/min. ED is average emitted dose (n=10); CV is coefficient of variation of emitted dose; FPF is fine 
particle fraction (geometric mean diameter <5µm); MMAD is mass median aerodynamic diameter; 
GSD is geometric standard deviation; EDeff is the emptying efficiency of powder from Twister 
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